Authors
Latest:
Dr. Walters on the Best Approach to Treating Patients With Stage III Lung CancerDustin M. Walters, MD, assistant professor, Thoracic and Cardiovascular Surgery, University of Virginia Health System, discusses the best approach to treating patients with stage III lung cancer.
Latest:
Dr. Fitch Discusses Dose Escalation of Radiation in Prostate CancerDwight L. Fitch, MD, Radiation Oncologist, 21st Century Oncology in Bradenton, Florida, discusses dose modifications for radiation therapy in patients with prostate cancer.
Latest:
Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 CombosDurvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.
Latest:
Dr. Crawford on Ongoing Trials of Genetic Testing for Prostate CancerE. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.
Latest:
Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost ImplicationsThere is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.
Latest:
Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate CancerAlthough prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.
Latest:
Poised Potential With Zenocutuzumab in NRG1+ Pancreatic CancerE. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.
Latest:
What to Look for in this IssueThe landscape for managing prostate cancer is changing rapidly. In recent months, we have seen two new drugs approved for hormone refractory advanced disease
Latest:
A Riddle, Wrapped in a Mystery, Inside an EnigmaAt last year's American Society of Clinical Oncology (ASCO) meeting, the official focus was on seeing personalized cancer medicine translated from a theoretical approach to a practical one. As you will see in this issue of Oncology & Biotech News, success is being realized on this front.
Latest:
Dr. Burgess on the Integration of PARP Inhibitors in Prostate CancerEarle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.
Latest:
Rx for Protection Rather Than For CurePhysicians tend to agree that the practice of defensive medicine is widespread, especially in oncology where much more is at stake than in the general practitioner's office. However, things can go drastically wrong.
Latest:
Dr. Santos on the Current Treatment Landscape in Squamous Cell Carcinoma of the LungEdgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.
Latest:
Key Takeaways in HER2-Mutated NSCLCThe panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.
Latest:
Back to the Future: Why Are More Women Having Bilateral Mastectomy for Unilateral Breast Cancer?Since 2003, the rate of women choosing breast-conserving surgery for the management of early-stage breast cancer has declined, with an accompanying recidivism to mastectomy. Edibaldo Silva, MD, PhD, examines the reasons for the treatment regression.
Latest:
Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast CancerEdith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.
Latest:
Dr. Mitchell on ECOG-ACRIN’s Efforts in Addressing Health Disparities in Cancer CareEdith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.
Latest:
Top 5 Contagion® News Articles for the Week of August 27, 2017Stay up-to-date on the latest infectious disease news by checking out this snapshot of our top 5 articles of the week.
Latest:
Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate CancerEdouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.
Latest:
Dr. Trabulsi Discusses Postoperative Radiation in Prostate CancerEdouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate CancerEduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Dr Sotomayor on the Integration of BTK Inhibitors into the CLL Treatment ArsenalEduardo Sotomayor, MD, discusses the current arsenal of BTK inhibitors in chronic lymphocytic leukemia.
Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck CancersResearchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
